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Colorectal cancer, which is the third most com-
mon cancer in men and the second most common 
in women, represents almost 10% of the annual 
global cancer incidence.1 Incidence rates of 
colorectal cancer show a strong positive gradient 
with an increasing level of economic develop-
ment.2 Even so, the net 5-year rate of survival 
decreases with lower levels of income, with rates 
reaching 60% in high-income countries but fall-
ing to 30% or less in low-income countries.3
Established risk factors for colorectal cancer 
include consumption of processed meats,4 con-
sumption of alcoholic beverages,5 tobacco smok-
ing,5 and excess body fat,6 whereas consumption 
of dietary fiber and dairy products and increased 
levels of physical activity decrease the risk.7,8 In 
addition, certain subgroups of the population 
are at increased risk owing to genetic predispo-
sition (e.g., the Lynch syndrome), a family or 
personal history of colorectal neoplasia, or med-
ical conditions (e.g., inflammatory bowel disease) 
that have been associated with colorectal cancer.
Colorectal cancer can be classified on the 
basis of the location within the large bowel, 
histologic characteristics, and molecular features. 
Advanced adenomas — in particular, those mea-
suring more than 10 mm in diameter — are the 
most well-known precursor lesions of colorectal 
cancer.9 Screening aims to reduce the risk of 
death from colorectal cancer through early de-
tection and the rate of complications associated 
with detection of cancer at a later stage. Such 
screening also aims to reduce the incidence and 
mortality of colorectal cancer through detection 
and removal of precancerous lesions. Colorectal 
cancer screening is available in many countries 
with high and upper-middle incomes worldwide 
and is delivered by organized programs or 
through opportunistic screening. Participation 
rates in such screening are highly variable among 
countries and settings10 but have typically been 
below 40%. Insurance status and access to pri-
mary care are the main determinants of partici-
pation. Additional obstacles include costs, logistic 
challenges, lack of provider involvement, language 
barriers, cultural beliefs, and lack of awareness 
of colorectal cancer screening.11,12
There are several methods available for colorec-
tal cancer screening. Stool-based tests to detect 
blood include the guaiac fecal occult blood test 
and the more sensitive fecal immunochemical 
test (FIT).13 Endoscopic methods, which use op-
tical approaches to directly examine the rectum 
and colon, include sigmoidoscopy and colonos-
copy.14 Colonoscopy is used both as a primary 
screening tool and as follow-up for persons who 
have tested positive with other screening meth-
ods. In addition, computed tomographic (CT) 
colonography, an imaging method based on 
scanning technology, has been developed as a 
less invasive visualization technique for colorec-
tal cancer screening.15 Newer techniques that 
have recently emerged but have not been widely 
tested are based on visual inspection (e.g., video 
capsule endoscopy) or the analysis of biomarkers 
in stool (e.g., multitarget-stool DNA), in blood 
(e.g., methylated septin 9 DNA), or in breath 
(e.g., volatile organic compounds and various 
markers of protein, RNA, and DNA).
We reviewed the published evidence from ran-
domized, controlled trials, observational studies, 
and modeling studies assessing stool-based, en-
doscopic, and CT colonography–based screening 
methods and evaluated outcomes with respect to 
preventive effects, adverse effects, and the bal-
ance of benefits and harms in average-risk popu-
lations of men and women combined. (Details 
regarding the working procedures that were 
used for conducting the review and a list of the 
members of the International Agency for Re-
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search on Cancer [IARC] Handbook Working 
Group are provided in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.)
In cases in which data from randomized tri-
als of the effect of a particular screening test on 
colorectal cancer mortality and incidence were 
not available, evidence regarding a similar screen-
ing test for which a reduction in colorectal can-
cer mortality or incidence has been shown (e.g., 
FIT instead of guaiac testing or colonoscopy in-
stead of sigmoidoscopy) or from comparative 
studies of test performance (e.g., CT colonogra-
phy instead of colonoscopy) was considered. 
Evidence regarding the above-mentioned newer 
techniques was considered insufficient to make 
an evaluation.
Here, we briefly summarize the evaluation of 
the scientific evidence, as reviewed by the Hand-
book Working Group (Table 1). The full report 
will be published as volume 17 of the IARC Hand-
books of Cancer Prevention. It is noteworthy 
that the majority of studies that were reviewed 
had been conducted in settings with middle or 
high incomes, in which the incidence of colorec-
tal cancer is generally high; in asymptomatic, 
average-risk populations (typically, between the 
ages of 50 and 70 years); and under conditions 
in which colorectal cancer screening, including 
subsequent follow-up and treatment, can be de-
livered with high quality. The extrapolation of the 
conclusions to different settings needs to take 
into account these and other context-related 
specificities (e.g., the level of health-system de-
velopment).
Stool-Based Tests for Occult 
Blood
Beneficial Effects of Guaiac Testing
We reviewed all the studies that assessed the 
effect of screening every 1 or 2 years with the 
guaiac fecal test in reducing the incidence of 
colorectal cancer, mortality associated with the 
Screening Technique Strength of Evidence Regarding Colorectal Cancer Screening
Reduction 
in Incidence
Reduction 
in Mortality
Benefit–Harm 
Ratio
Stool-based tests
Screening every 2 yr with guaiac test 
without rehydration
Suggestive of a lack 
 of effect
Sufficient Sufficient
Screening every 1 or 2 yr with higher‑
sensitivity guaiac test (with rehydra‑
tion)
Limited Sufficient Sufficient
Screening every 2 yr with FIT Limited Sufficient Sufficient†
Endoscopic techniques
Single screening with sigmoidoscopy Sufficient Sufficient Sufficient
Single screening with colonoscopy Sufficient Sufficient Sufficient‡
CT colonography
Single screening with CT colonography Limited§ Limited§ Inadequate
*  The finding of sufficient evidence applies only to settings in which it is assumed that screening, along with treatment 
and follow‑up, can be delivered with high quality. FIT denotes fecal immunochemical test.
†  A variety of qualitative and quantitative FIT tests are available, with wide ranges of sensitivity and specificity. The net 
balance of benefits and harms depends on the cutoff level for positivity.
‡  A minority of the members of the International Agency for Research on Cancer (IARC) Handbook Working Group con‑
sidered that the evidence is limited because of the variability of the effect estimates, the risks associated with colonos‑
copy, and the inherent limitations in extrapolating conclusions from data regarding screening with sigmoidoscopy.
§  The evaluation of limited evidence regarding CT colonography applies to the reduction in incidence or mortality (one 
single evaluation). A minority of the members of the IARC Handbook Working Group considered that the evidence is 
inadequate because of the lack of randomized trials or observational studies (including those with repeated CT colonog‑
raphy screening) and lack of data regarding risks.
Table 1. Evaluations of Colorectal Cancer Screening with Stool-Based Tests, Endoscopic Methods, and Computed 
Tomographic (CT) Colonography.*
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disease, or both. These studies included 5 ran-
domized trials that were performed in North 
America or Western Europe16-20 and 10 observa-
tional studies conducted in screening settings 
that were performed in different geographic re-
gions.21-30 In these studies, the investigators per-
formed guaiac testing either without rehydration 
or with hydration, with the latter test having a 
higher sensitivity (Table 1).
On the basis of the results of two random-
ized trials, two large cohort studies with up to 
11 screening rounds, and one case–control 
study,16,19,23,24,26 there is sufficient evidence that 
screening every 2 years with the guaiac test 
without rehydration reduces colorectal cancer 
mortality, as does screening every 1 or 2 years 
with the higher-sensitivity guaiac test.17,20,25 In 
the randomized trials, the relative risk of death 
from colorectal cancer was significantly lower 
among the persons with a positive test result 
who had undergone guaiac testing coupled with 
colonoscopy than among controls (no screening); 
the relative risks were 9 to 14% lower with 
guaiac testing without rehydration and 16 to 
32% lower with higher-sensitivity guaiac testing.
The evidence suggests a lack of effect of 
screening every 2 years with the guaiac test 
without rehydration in reducing the incidence of 
colorectal cancer on the basis of three random-
ized trials and one cohort study after 11 screen-
ing rounds.16,18,19,24 In addition, there is limited 
evidence that screening every 1 or 2 years with 
the higher-sensitivity guaiac test reduces such 
incidence, on the basis of one randomized trial 
with 18 years of follow-up.31
Beneficial Effects of FIT
To our knowledge, no randomized trials of FIT 
with data on incidence or mortality outcomes 
have been performed, but the findings from 
observational studies in screening settings were 
highly consistent. Three cohort studies, includ-
ing one incidence-based mortality study, showed 
relative risks of death from colorectal cancer 
that were 10 to 40% lower among persons who 
had undergone FIT screening than among con-
trols.32-34 One ecologic study in Italy that com-
pared areas that had early implementation 
(2002–2004) of an organized program of FIT 
screening every 2 years versus late implementa-
tion (2008–2009) also showed a lower relative 
risk of death from colorectal cancer in the area 
where screening was introduced first than in the 
area with later implementation.35 Overall, there is 
sufficient evidence that screening every 2 years 
with FIT reduces colorectal cancer mortality. 
This evaluation also takes into account evidence 
from randomized trials of guaiac testing, from 
which we can infer that FIT should be at least as 
good as guaiac testing in reducing colorectal 
cancer mortality, and evidence from randomized 
trials showing that FIT performed better than 
guaiac testing for the detection of advanced ad-
enoma and colorectal cancer.
The evidence was deemed to be limited with 
respect to lowering the incidence of colorectal can-
cer. Small-to-moderate reductions in cumulative 
incidence were observed in two cohort studies after 
three rounds of FIT performed every 2 years33,34 
and in one ecologic study conducted in Italy.36
Potential Harms and Benefit–Harm Ratios
Potential harms of screening with stool-based 
tests for occult blood are related to psychologi-
cal harms of screening per se and of receiving a 
positive test result, harms that were reported to be 
mild and transitory.37,38 In addition, unnecessary 
referrals and medical harms linked to follow-up 
colonoscopy and surveillance after a positive test 
can occur. In modeling studies, all stool-based 
tests for occult blood provided gains in quality-
adjusted life-years, as compared with no screen-
ing, especially FIT and higher-sensitivity guaiac 
testing.39 Overall, there is sufficient evidence that 
the benefits outweigh the harms of colorectal 
cancer screening with any type of stool-based 
test for occult blood.
Endoscopic Methods
Four large, randomized trials of sigmoidoscopy 
screening — three in Europe and one in the 
United States40-43 — have been performed. In all 
the studies that evaluated the relative risk of 
colorectal cancer, such incidence was signifi-
cantly lower (18 to 26%) among persons who 
had undergone sigmoidoscopy screening than 
among those who had not; the relative risk of 
death from colorectal cancer was also signifi-
cantly lower (22 to 31%) in all but one study.43 
An extended follow-up of one trial up to 17 years 
showed a persistently significant lower relative 
risk of 26% in colorectal cancer incidence and of 
30% in colorectal cancer mortality in intention-
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to-treat analyses.44 Four randomized trials of 
colonoscopy are currently in progress, but data 
on the effect on colorectal cancer incidence or 
mortality are not yet available.
A large number of observational studies were 
available for review, but only those that were 
performed in a screening setting (conducted 
mainly in the United States) were included for 
evaluation. Two cohort studies45,46 provided esti-
mates on colorectal cancer incidence, mortality, 
or both associated with sigmoidoscopy, and five 
cohort studies46-50 provided such data associated 
with colonoscopy. In addition, case–control stud-
ies, including several studies involving more than 
2000 persons, provided risk estimates for sig-
moidoscopy (nine studies) and colonoscopy (five 
studies). In most cohort and case–control stud-
ies, the relative risks of incidence and death were 
significantly lower among persons who had un-
dergone either sigmoidoscopy or colonoscopy 
than among controls, although relative risks var-
ied greatly among the studies. The most recent 
meta-analysis of observational studies estimated 
risk reductions in both incidence and mortality 
of almost 70% with colonoscopy and almost 50% 
with sigmoidoscopy. The effect was consistently 
stronger in the distal colon than in the proximal 
colon.51
There is sufficient evidence that a single 
screening with sigmoidoscopy or colonoscopy 
reduces colorectal cancer incidence and mortal-
ity (Table 1). In addition to considering the con-
sistent results from the observational studies of 
colonoscopy, this evaluation also takes into ac-
count evidence from randomized trials of sig-
moidoscopy screening, since a full colonoscopy, 
by definition, includes a sigmoidoscopy, and if we 
assume that there will be similar false negative 
rates for both procedures, colonoscopy will be at 
least as effective as sigmoidoscopy in detecting 
advanced adenomas and colorectal cancer. Cur-
rently, there is insufficient evidence to assess 
the benefit of subsequent rounds of endoscopic 
screening.
Similar to stool-based tests for occult blood, 
endoscopic screening may generate psychologi-
cal harms, along with unnecessary referrals after 
positive results on sigmoidoscopy. In addition, 
endoscopy may provoke serious medical harms, 
of which bleeding and perforation are the most 
frequent, although such adverse events remain 
uncommon, with each event occurring in 0.01 to 
0.05% of colonoscopy procedures.52 The propor-
tion of overdiagnosis of cancer from endoscopic 
screening is uncertain.
In modeling studies, sigmoidoscopy and colo-
noscopy both provide gains in quality-adjusted 
life-years, as compared with no screening.53 
Overall, there is sufficient evidence that the bene-
fits of a single screening with sigmoidoscopy 
outweigh the harms. The consensus was that 
there is sufficient evidence that the benefits of a 
single screening with colonoscopy also outweigh 
the harms, when screening can be delivered with 
high quality. A minority of the expert panel 
members considered that the evidence is limited 
because of the variability and the related limited 
accuracy of the effect estimates, the harms asso-
ciated with colonoscopy, and the inherent limita-
tions in extrapolating findings regarding sig-
moidoscopy to evaluate colonoscopy.
C T Colonogr aphy
To our knowledge, no published, randomized 
trials have assessed the effect of CT colonogra-
phy screening on colorectal cancer incidence or 
mortality. One randomized trial54 and four tan-
dem studies55-58 with consecutive or parallel screen-
ing of asymptomatic persons compared rates of 
adenoma detection with CT colonography versus 
those with colonoscopy and were considered to 
be informative for the evaluation. In the tandem 
studies (a comparison study in which the same 
person was screened sequentially with two 
methods), the detection rates of advanced neo-
plasia (advanced adenoma or cancer) were simi-
lar with both techniques; in the randomized trial, 
detection rates with CT colonography, as com-
pared with colonoscopy, were similar for colorec-
tal cancer but were lower for all advanced adeno-
mas (5.6% vs. 8.2%) and for advanced adenomas 
measuring at least 10 mm (5.4% vs. 6.3%); this 
difference disappeared after adjustment for par-
ticipation rate.
Potential harms that are associated with CT 
colonography include radiation-induced effects, 
the downstream effects from detection of extra-
colonic findings,59 and the potential harms of 
follow-up colonoscopy. On the basis of these 
data, there is limited evidence that a single 
screening with CT colonography reduces colorec-
tal cancer incidence or mortality. A minority of 
the expert panel members considered that the 
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evidence is inadequate because of the lack of 
randomized trials or observational studies with 
incidence or mortality as end points, the lack of 
studies with repeated CT colonography screen-
ing, the fact that data regarding only test perfor-
mance and adenoma detection rates were avail-
able, and the wide extrapolation needed from the 
known detection rates of lesions to an expected 
reduction in colorectal cancer incidence or mor-
tality in a screening setting. Finally, there is in-
adequate evidence that the benefits of a single 
round of screening with CT colonography out-
weigh the harms.
Compar ative Effec tiveness  
of Screening Techniques
Comparisons of reductions in colorectal cancer 
incidence and mortality with stool-based meth-
ods versus endoscopic methods were available 
from network meta-analyses (indirect compari-
sons of studies of screening versus no screening). 
One meta-analysis of nine randomized trials60 
showed that sigmoidoscopy performed better 
than guaiac testing in reducing colorectal cancer 
incidence but not mortality. Another meta-analy-
sis that included both randomized trials and ob-
servational studies in screening settings61 showed 
that colonoscopy was more effective than sig-
moidoscopy and guaiac testing in reducing 
colorectal cancer mortality, although the quality 
of the evidence was low because of the heteroge-
neity in study designs and inherent biases in 
such comparisons. In addition, when comparing 
the performance of a single screening round, 
endoscopic techniques, especially sigmoidoscopy, 
generally yielded higher detection rates of ad-
vanced neoplasia than one-time stool-based tests 
for occult blood.62-65 However, recent data sug-
gest that detection rates of advanced neoplasia 
with FIT performed every 2 years over five con-
secutive screening rounds were similar to those 
with one-time colonoscopy.66 Taken together, the 
evidence was considered to be insufficient to 
evaluate the comparative effectiveness of the 
available screening techniques.
In conclusion, there is sufficient evidence that 
screening for colorectal cancer with currently 
established stool-based tests (guaiac testing and 
FIT) and lower endoscopy (sigmoidoscopy and 
colonoscopy) reduces the risk of death from 
colorectal cancer and that the benefits outweigh 
the harms associated with each type of screen-
ing. Evidence from comparative effectiveness 
studies to evaluate one test over another was 
inconclusive.
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